It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The World Health Organization will convene an ethics panel next week to discuss whether the experimental drug ZMapp should be given to some Ebola patients across West Africa.
A nurse in Nigeria. A businessman in Saudi Arabia. A Spanish priest in Liberia.
Meanwhile, the World Health Organization began a meeting to decide whether the crisis, the worst recorded outbreak of its kind, amounts to an international public health emergency. At least 932 deaths in four countries have been blamed on the illness, with 1,711 reported cases.
At the top of their agenda: to advise whether the outbreak constitutes a Public Health Emergency of International Concern. That's a formal designation that would open the way for WHO's Director-General, Dr. Margaret Chan, to recommend "extraordinary measures," such as travel and trade restrictions in the region. These would not be binding. But they would carry considerable weight.
The number of people to have died in the worst Ebola outbreak in history has risen to at least 932, the World Health Organization said on Wednesday, as overworked hospital staff struggled to quell the epidemic and in many cases became its front-line victims.
Between Saturday and Monday, 45 people died of the disease in West Africa, while the number of cases in the region rose by 108, the WHO reported as it began a two-day emergency meeting in Geneva to determine whether the outbreak constitutes a public-health emergency and how to address it.
originally posted by: Destinyone
a reply to: crazyewok
That makes sense CE...they have X amount for 2 people, but no clue how much it will take per person. To our knowledge, this is the first time it's being used on humans.
But the Media running with a giant splash of, they found the miracle one dose cure for ebola, is all that people are going to remember.
The current outbreak is caused by a variant of Zaire Ebolavirus with 97% sequence identity to strains isolated from the DRC and Gabon, suggesting a parallel evolution of this virus in the affected area as opposed to introduction from these endemic areas.
The disease progresses rapidly to multisystem involvement that may include systemic, gastrointestinal, respiratory and vascular features.
I.B.3.b. Droplet transmission:
Droplet transmission is, technically, a form of contact transmission, and some infectious agents transmitted by the droplet route also may be transmitted by the direct and indirect contact routes.
The maximum distance for droplet transmission is currently unresolved, although pathogens transmitted by the droplet route have not been transmitted through the air over long distances, in contrast to the airborne pathogens discussed below. Historically, the area of defined risk has been a distance of less than 3 feet around the patient and is based on epidemiologic and simulated studies of selected infections 103, 104.
Droplet size is another variable under discussion. Droplets traditionally have been defined as being greater than 5 μm in size. Droplet nuclei, particles arising from desiccation of suspended droplets, have been associated with airborne transmission and defined as less than 5 μm in size...
Observations of particle dynamics have demonstrated that a range of droplet sizes, including those with diameters of 30μm or greater, can remain suspended in the air. The behavior of droplets and droplet nuclei affect recommendations for preventing transmission. Whereas fine airborne particles containing pathogens that are able to remain infective may transmit infections over long distances, requiring AIIR to prevent its dissemination within a facility; organisms transmitted by the droplet route do not remain infective over long distances, and therefore do not require special air handling and ventilation.
I.B.3.c. Airborne transmission:
Airborne transmission occurs by dissemination of either airborne droplet nuclei or small particles in the respirable size range containing infectious agents that remain infective over time and distance (e.g., spores of Aspergillus spp, and Mycobacterium tuberculosis).
Droplets from coughs and sneezes travel farther than you think
It is common knowledge that when we cough or sneeze, we should cover our mouth and nose with a tissue to prevent germs from becoming airborne. Now, new research from the Massachusetts Institute of Technology suggests this instruction is more important than ever; they found that droplets from coughs or sneezes can travel up to 200 times farther than previously thought.
The team found that, contrary to previous beliefs, each droplet from a cough or sneeze is connected through interaction with a gas cloud.
Droplets that are 100 micrometers in diameter were found to travel five times farther than past estimates, while droplets 10 micrometers in diameter were found to travel 200 times farther. In addition, the team found that droplets less that 50 micrometers in size are often able to stay airborne long enough to enter ceiling ventilation units.
SURVIVAL OUTSIDE HOST: The virus can survive in liquid or dried material for a number of days (23). Infectivity is found to be stable at room temperature or at 4°C for several days, and indefinitely stable at -70°C (6, 20). Infectivity can be preserved by lyophilisation.
It is an elongated filamentous molecule, which can vary between 800 - 1000 nm in length, and can reach up to14000 nm long (due to concatamerization) with a uniform diameter of 80 nm.
originally posted by: 00nunya00
a reply to: ~Lucidity
Your YouTube is broken, Luc.
Crazyewok: exactly. A few years from now, we will know if it was the serum that saved Brantley, or just his superior immune system bolstered by western-hemisphere living. :/ Still worth a shot, though, I guess.
originally posted by: ikonoklast
a reply to: Destinyone
Des (and all), I thought you might want to know that I have updated the charts/graphs showing the rate this outbreak is spreading at. They are posted here:
Ebola - my visual charts & projections based on WHO data
The original charts were based on a little more than 4 months of data from WHO, but I found a lot more data from The New England Journal of Medicine and now have a little more than 9 months of data... starting from the presumed first case, on December 2, 2013!
originally posted by: 00nunya00
A third dose? Seriously? Please link? This is ridiculous now. How many are they hiding?
GUPTA: And, Michaela, I should point out we first reported about this experimental serum, this experimental medication Monday morning. We now know -- that was the two doses she received in Liberia. We now know she's going to get that third dose here at Emory University. The doctors here have been talking to representatives from the NIH and the FDA to make that happen.
So, it would be the third and final dose for her we believe today, Michaela.